Wells Fargo Maintains Overweight on Helus Pharma, Raises Price Target to $22

Benzinga · 2d ago
Wells Fargo analyst Benjamin Burnett maintains Helus Pharma (NASDAQ:HELP) with a Overweight and raises the price target from $16 to $22.